Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2025-10-27 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
第五届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fifth board of directors' third meeting of Anhui 峆一药业股份有限公司. It includes details about the meeting date, attendance, and the approval of the company's 2025 third quarter report. However, the actual 2025 third quarter report is not included here; instead, the document references that report as being disclosed on the Beijing Stock Exchange information platform. The document is primarily a board meeting resolution announcement rather than the report itself. Therefore, it fits best under Board/Management Information (MANG) as it announces board decisions and meeting outcomes related to company reports but does not contain the report or financial data itself.
2025-10-27 Chinese
2025年三季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "2025 年第三季度报告" which translates to "2025 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the period ending September 30, 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter and year-to-date periods. It is unaudited but contains substantive financial data and management commentary. This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. 9M 2025
2025-10-27 Chinese
国元证券股份有限公司关于安徽峆一药业股份有限公司2025年半年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a '2025 年半年度持续督导跟踪报告' which translates to '2025 Semi-Annual Continuous Supervision Follow-up Report' issued by the sponsor Guoyuan Securities Co., Ltd. for Anhui Yi Pharmaceutical Co., Ltd. It references regulatory rules related to securities issuance and listing, and details the sponsor's ongoing supervision work, findings, measures taken, company commitments, risks, and other related matters. The document is a detailed report on the sponsor's continuous supervision activities for a half-year period, including financial and operational oversight, but it is not a full interim or quarterly financial report with substantive financial statements. It is a specialized regulatory follow-up report by the sponsor, which aligns with the definition of an Audit Report / Information (AR) as it includes audit-related oversight, compliance, and internal control review information, but is not a full annual or interim report. The document length is 3670 characters, which is relatively short but contains substantive content beyond a mere announcement. Therefore, the best fitting category is AR (Audit Report / Information). H1 2025
2025-09-03 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 安徽峆一药业股份有限公司 dated September 2025. It contains detailed provisions about the company's organization, shareholder rights, board of directors, management, financial accounting, profit distribution, audit, shareholder meetings, and other governance matters. It references relevant laws and regulations such as the Company Law, Securities Law, and Beijing Stock Exchange listing rules. The content is a comprehensive governance document outlining the internal rules and structure of the company rather than a financial report, announcement, or meeting material. Therefore, this document fits the category of Governance Information (CGR).
2025-09-03 Chinese
2025年第三次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the "2025 Third Extraordinary General Meeting of Shareholders" of Anhui Xuyi Pharmaceutical Co., Ltd. It details the meeting date, attendance, voting results on various proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official voting results and decisions made at the shareholders meeting, including amendments to company bylaws and capital changes. The document is relatively short (3639 characters) and is a formal announcement of the meeting's resolutions and voting outcomes rather than the full meeting materials or presentations. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)" which covers official results from shareholder votes at any general meeting. Therefore, the correct classification is DVA.
2025-09-03 Chinese
上海德禾翰通律师事务所关于安徽峆一药业股份有限公司2025年第三次临时股东会的法律意见书
Regulatory Filings Classification · 78% confidence The document is a legal opinion letter (“法律意见书”) issued by a law firm on the convening, procedure, attendance qualifications, and voting results of an extraordinary shareholders’ meeting. It is not the meeting materials themselves (AGM/EGM presentation), nor is it the official company notice of resolutions but rather a legal compliance opinion. It does not contain substantive financial statements or management discussion, nor is it a proxy solicitation. It is best classified as a general regulatory compliance filing under “Regulatory Filings (RNS).”
2025-09-03 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.